Tuning In to The C-Suite / David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.